Tacabrutideg

Tier C — Watch / trade

Tacabrutideg

BeiGene, Ltd.

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：BTK

Indications (approved)：Chronic lymphocytic leukaemia, B-cell lymphoma, B淋巴细胞白血病, 里氏综合征, Marginal zone B-cell lymphoma, Non-Hodgkin lymphoma, Waldenström macroglobulinaemia, Follicular lymphoma

Regional status

Phase III

2025-04-10

Phase III

2025-04-10

China

Phase III

2025-05-29

Japan

Phase III

2025-04-10

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Tacabrutideg?

Approved indications include: Chronic lymphocytic leukaemia, B-cell lymphoma, B淋巴细胞白血病, 里氏综合征, Marginal zone B-cell lymphoma, Non-Hodgkin lymphoma, Waldenström macroglobulinaemia, Follicular lymphoma.

When does the Tacabrutideg patent expire?

No public expiry year is available for Tacabrutideg yet; this page updates once verified.

How do I get a quote for Tacabrutideg intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-30